scholarly journals Sentinel node biopsy in clinical stage I testicular cancer enables early detection of occult metastatic disease

2019 ◽  
Vol 124 (3) ◽  
pp. 424-430 ◽  
Author(s):  
Joost M. Blok ◽  
J. Martijn Kerst ◽  
Erik Vegt ◽  
Oscar R. Brouwer ◽  
Richard P. Meijer ◽  
...  
Keyword(s):  
Early Detection ◽  
Testicular Cancer ◽  
Sentinel Node ◽  
Sentinel Node Biopsy ◽  
Metastatic Disease ◽  
Clinical Stage ◽  
Stage I ◽  
Node Biopsy ◽  
Occult Metastatic Disease

Socioeconomic and demographic factors associated with use of sentinel node biopsy and adjuvant biologic response modifiers in melanoma

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 6027-6027 ◽  
Author(s):  
J. R. Lange ◽  
D. Chang ◽  
B. E. Palis ◽  
C. M. Balch
Keyword(s):  
Sentinel Node ◽  
Sentinel Node Biopsy ◽  
Clinical Stage ◽  
Stage I ◽  
Cancer Management ◽  
Node Biopsy ◽  
Insurance Type ◽  
Regional Metastases ◽  
Biologic Response ◽  
Socioeconomic And Demographic Factors

6027 Background: Cancer management may be influenced by factors other than disease characteristics. Little is known about the association of demographic and socioeconomic factors with melanoma care. Methods: The National Cancer Data Base, a hospital-based registry, was queried on reported use of adjuvant biologic response modifiers (BRM) for patients with resected regional metastases and the use of sentinel node biopsy (SNBx) for patients with clinical stage I and II melanoma in patients ages 1–69 between 1994 and 2003. Independent variables were age, sex, race, severity of disease, income, insurance type, U. S. Census region and type of treating facility. Analysis was performed by forward stepwise logistic regression. Results: Between 1994 and 2003, 37.8% of 10,790 patients with resected node-positive melanoma received BRM. Between 1998 and 2002, 61,251 patients with clinical stage I and II melanoma had a SNBx in 13.2%, 46.2%, 55.9%, and 41.7% of those with T1, T2, T3, and T4 tumors, respectively. In multivariate analysis, geographic variance in use of BRM and SNBx was striking ( Table ). Insurance type (commercial vs. others) and facility type (teaching/research vs. others) were also significantly associated with these modalities. Use of BRM was also associated with age, number of positive nodes and earlier treatment year, but not with sex, income or race. Use of SNBx was also associated with T stage, later treatment year, age and income, but not with sex or race. Conclusions: BRM and SNBx use varied significantly with geographic region, insurance type, and type of treating facility; this may have implications for provider education and public policy. [Table: see text] No significant financial relationships to disclose.

Sentinel node biopsy in clinical stage I testicular cancer.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 550-550
Author(s):  
Joost Marijn Blok ◽  
Richard Paul Meijer ◽  
Jan M. Kerst ◽  
Erik Vegt ◽  
Ruud Bosch ◽  
...  
Keyword(s):  
Sentinel Node ◽  
Metastatic Disease ◽  
Early Identification ◽  
Clinical Stage ◽  
Stage I ◽  
Long Term Results ◽  
X Rays ◽  
Occult Metastases ◽  
Occult Metastatic Disease

550 Background: Approximately 20 – 30% of patients with testicular germ cell tumors (TGCTs) in clinical stage I (CS I) have occult metastatic disease at the time of presentation and will relapse under surveillance. The availability of a sentinel node procedure would enable early identification of patients with occult metastases. We report the long-term results of the sentinel node approach in CS I testicular tumor patients in our facility. Methods: Between 2001 and 2015, patients suspected of CS I TGCT in our third echelon referral center were asked to participate. SNs were identified using SPECT/CT and/or lymphoscintigraphy. Participants underwent laparoscopic retroperitoneal SN excision together with inguinal orchiectomy. Patients with a SN positive for occult metastases were treated with adjuvant chemotherapy. Follow-up was according to then current guidelines and consisted of clinical examination, tumor markers, abdominal/thoracic CT-scanning and chest X-rays. Results: Twenty-seven patients were included. In two patients, no sentinel nodes were visualized on scintigraphy. In twenty-five patients, a median of 3 SNs (range 1 – 4) per patient were removed. Two patients showed no malignancy on histopathologic examination of the testis. Of the 23 patients diagnosed with TGCT, three (13.0%) had occult metastatic disease. All 23 patients were without evidence of disease at a median follow-up of 62.2 months (range 22.3 – 143.4). Conclusions: The SN procedure enables early identification of patients with occult metastatic disease in CS I TGCT. Clinical trial information: M00LMT.

scholarly journals SPECT/CT and a Portable  -Camera for Image-Guided Laparoscopic Sentinel Node Biopsy in Testicular Cancer

2011 ◽  
Vol 52 (4) ◽  
pp. 551-554 ◽  
Author(s):  
O. R. Brouwer ◽  
R. A. Valdes Olmos ◽  
L. Vermeeren ◽  
C. A. Hoefnagel ◽  
O. E. Nieweg ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Sentinel Node ◽  
Sentinel Node Biopsy ◽  
Image Guided ◽  
Node Biopsy ◽  
Portable Camera

Surgical management of stage I and II vulvar cancer: The role of the sentinel node biopsy. Review of literature

2001 ◽  
Vol 11 (4) ◽  
pp. 255-262 ◽  
Author(s):  
A. P. H. Makar ◽  
M. Scheistroen ◽  
D. Van Den Weyngaert ◽  
C. G. Tropé
Keyword(s):  
Sentinel Node ◽  
Sentinel Node Biopsy ◽  
Surgical Management ◽  
Vulvar Cancer ◽  
Early Stage ◽  
Stage I ◽  
Review Of Literature ◽  
Early Stage Disease ◽  
Node Biopsy

Abstract.Makar APH, Scheistroen M, van den Weyngaert D, Tropé CG. Surgical management of stage I and II vulvar cancer: The role of the sentinel node biopsy. Review of literature.Recognition of the psychosexual consequences of radical vulvectomy and better understanding of the lymphatic drainage and histopathologic features of vulvar cancer have led to a more conservative surgical approach, especially in patients with early-stage disease. Every patient with early vulvar cancer should be managed individually and the risk of conservative therapy balanced against the dangers and advantages of more radical therapy. The results of the sentinel node (SN) procedure in early cancer of the vulva are encouraging, and it might be possible in the near future to avoid the morbidity of inguino-femoral lymphadenectomy. This article reviews surgical management of early vulvar cancer and the place of SN biopsy.

Sentinel lymph node biopsy in clinical stage I testicular cancer

2018 ◽  
Vol 17 (13) ◽  
pp. e2745
Author(s):  
J.M. Blok ◽  
M. Kerst ◽  
E. Vegt ◽  
O. Brouwer ◽  
R. Meijer ◽  
...  
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Sentinel Lymph Node Biopsy ◽  
Testicular Cancer ◽  
Clinical Stage ◽  
Lymph Node Biopsy ◽  
Stage I ◽  
Node Biopsy

Sentinel node biopsy in primary breast cancer: Radioactive detection and metastatic disease

2007 ◽  
Vol 33 (6) ◽  
pp. 691-695 ◽  
Author(s):  
N. Wada ◽  
N. Sakemura ◽  
S. Imoto ◽  
T. Hasebe ◽  
A. Ochiai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Sentinel Node ◽  
Sentinel Node Biopsy ◽  
Metastatic Disease ◽  
Primary Breast Cancer ◽  
Node Biopsy ◽  
Radioactive Detection
Sign in / Sign up

Export Citation Format

Share Document